Common questions about CJC-1295, answered from the research record.

What is CJC-1295 and how does it differ from Modified GRF 1-29?

CJC-1295 is a synthetic 30-amino acid analog of growth hormone-releasing hormone (GHRH) developed by ConjuChem Biotechnologies. It was designed to overcome the rapid enzymatic breakdown that limits native GHRH's usefulness — native GHRH has a plasma half-life of only 7–10 minutes.

CJC-1295 achieves prolonged activity through two mechanisms: four amino acid substitutions (including D-Ala at position 2) that resist DPP-IV enzymatic cleavage, and a Drug Affinity Complex (DAC) — a reactive maleimide group that spontaneously bonds to Cys34 on serum albumin after injection, creating a long-circulating reservoir. The result is a plasma half-life of 5.8–8.1 days in humans ^[3].

Modified GRF 1-29 shares the four amino acid substitutions but lacks the DAC moiety. Its half-life is approximately 30 minutes — meaningfully longer than native GHRH but roughly 300-fold shorter than CJC-1295 DAC ^[13]. The two compounds produce different GH secretion profiles: Mod-GRF 1-29 produces sharper, shorter GH pulses; CJC-1295 produces sustained GH elevation at chronically elevated mean levels. They are often confused because of the 'CJC-1295 without DAC' label, but they are pharmacokinetically distinct compounds.

Is CJC-1295 legal — what is its FDA regulatory status in 2024–2026?

CJC-1295 is not an FDA-approved drug. No approved New Drug Application exists for any indication, and no active Investigational New Drug application for commercial development is on file as of mid-2026. It is not a scheduled controlled substance under the Controlled Substances Act.

For licensed compounding pharmacies, the status changed materially in 2024. CJC-1295 was removed from the FDA's interim 503A Category 2 bulks list in September 2024 after nominators withdrew ^[15]. The FDA Pharmacy Compounding Advisory Committee then reviewed it on December 4, 2024 and voted against inclusion on the 503A Bulks Regulation, citing cardiovascular adverse event reports, immunogenicity concerns, and insufficient compounding-specific safety data ^[14]. As of mid-2026, compounding of CJC-1295 by 503A pharmacies is not authorized under current FDA guidance — no Federal Register notice permitting it has been published.

The 'not scheduled' DEA status means it is not a federally controlled substance, but this should not be read as regulatory clearance. Absence of scheduling is a different question from FDA approval or compounding authorization.

Is CJC-1295 banned by WADA and other anti-doping organizations?

Yes. CJC-1295 is explicitly prohibited by the World Anti-Doping Agency under Section S2.2.4 (Growth Hormone Releasing Factors) of the WADA Prohibited List ^[16]. The prohibition applies year-round — both in-competition and out-of-competition — for any athlete subject to anti-doping rules.

Strict liability applies under WADA rules, meaning athletes are responsible for prohibited substances in their systems regardless of whether use was intentional. U.S. Department of Defense military anti-doping protocols incorporate WADA standards, so the prohibition extends to service members subject to military testing.

WADA-accredited laboratories can detect CJC-1295 at picogram-per-milliliter levels using combined immuno-PCR and LC-MS/MS methods. LC-HRMS/MS identification of CJC-1295 was published by anti-doping researchers following a forensic analysis of an illicit preparation submitted by Norwegian authorities ^[9]. Validated methods for equine plasma (relevant to horse racing anti-doping) achieve detection at 0.8 pg/mL using immuno-PCR ^[10] and 180 pg/mL using LC-MS/MS with immunoaffinity capture ^[11].

Can compounding pharmacies still make CJC-1295 after the 2024 PCAC decision?

Under current FDA guidance, no. The PCAC voted against inclusion on the 503A Bulks Regulation on December 4, 2024 ^[14]. This was a non-binding advisory vote, but the FDA's direction is clear from the agency documents and the vote outcome.

The regulatory sequence was: CJC-1295 was nominated for the 503A Category 2 interim list (substances under evaluation with safety concerns), then removed from that list in September 2024 after nominators withdrew ^[15], then reviewed by PCAC in December 2024 with a negative recommendation. As of mid-2026, no Federal Register notice authorizing CJC-1295 compounding by 503A pharmacies has been published.

This means licensed compounding pharmacies operating under 21 U.S.C. § 503A do not have a clear legal basis for compounding CJC-1295. The regulatory gap between what research literature studies and what compounding pharmacies can legally produce is part of what makes the 'is it legit?' question genuinely complicated.

How does CJC-1295's Drug Affinity Complex (DAC) mechanism work?

The DAC (Drug Affinity Complex) is a chemical modification technology developed by ConjuChem Biotechnologies. A reactive maleimide group is attached to the lysine residue at CJC-1295's C-terminus via a maleimidopropionic acid linker. After subcutaneous injection, this maleimide group undergoes a Michael addition reaction with the free sulfhydryl (–SH) group of cysteine-34 (Cys34) on circulating serum albumin, forming a stable thioether bond ^[12].

This reaction occurs in vivo: Western blot studies in Sprague Dawley rats detected the albumin-CJC-1295 conjugate in plasma within 15 minutes of injection, persisting beyond 24 hours ^[6][12]. The resulting macromolecular conjugate is approximately 67 kDa — too large for glomerular filtration and resistant to proteolytic enzymes. Albumin's own plasma half-life is approximately 19 days, so the conjugate circulates as a slowly releasing depot.

The analytical consequence is important: because the DAC-bound form is too large for standard mass spectrometry, detecting CJC-1295 in plasma requires specialized methods — immuno-PCR or immunoaffinity capture followed by enzymatic digestion before LC-MS/MS ^[10][11].

What does published research say about CJC-1295's effects on growth hormone and IGF-1?

The Teichman 2006 Phase 1/2 trial ^[1][2][3] — the primary human evidence — found that a single subcutaneous injection at 30–120 μg/kg produced dose-dependent 2- to 10-fold increases in mean plasma GH concentrations lasting six days or more in healthy adults. Mean plasma IGF-1 rose 1.5- to 3-fold and remained elevated for 9–11 days after a single injection. Multiple doses (weekly or twice-weekly at 30–60 μg/kg) maintained IGF-1 above baseline for up to 28 days after the final dose. Pulsatile GH secretion was preserved throughout — a feature that distinguishes GHRH analogs from exogenous GH therapy.

A 2009 study ^[8] found five significant serum protein fraction changes after a single 60–90 μg/kg dose in healthy men, indicating downstream proteomic effects beyond IGF-1 elevation alone.

In animal models, CJC-1295 produced a 4-fold increase in GH AUC relative to unconjugated GRF(1-29) in rats ^[6], and normalized growth parameters in GHRH-knockout mice over five weeks of once-daily dosing ^[4][5].

What are the known risks and safety concerns with CJC-1295 research?

The research and regulatory record identifies several areas of concern:

Cardiovascular signals: One participant in the Phase 2 HIV lipodystrophy trial died of a myocardial infarction. The investigator attributed the event to pre-existing coronary artery disease, but the FDA PCAC December 2024 review flagged cardiovascular adverse event reports as a contributing concern in their negative vote ^[14].

Chronic IGF-1 elevation: CJC-1295 produces sustained rather than pulsatile IGF-1 elevation. Epidemiological data link high-normal to elevated IGF-1 with increased risk of certain cancers (colorectal, prostate) over long timeframes. Long-term human safety data for sustained IGF-1 elevation from CJC-1295 do not exist ^[17].

Immunogenicity: The albumin-conjugated form carries immunogenicity risk, particularly from impurities in unregulated preparations. This was flagged by the PCAC ^[14].

Grey-market preparation quality: Independent analysis of illicit preparations has found purity variance from 91.2% to 99.1%, even in products labeled >95% pure ^[9]. CJC-1295 was forensically identified in an unauthorized preparation submitted to anti-doping authorities ^[9].

Human data gap: All primary human data are from short-term trials (28–49 days) in healthy adults. No long-term human safety data exist. A 2026 sports medicine review characterized the human safety evidence as scarce ^[17].

How do I verify that CJC-1295 from a research supplier is authentic and not contaminated?

This site does not evaluate or recommend suppliers. However, the research literature is informative about the analytical challenges involved.

Standard mass spectrometry (LC-MS/MS) may miss the albumin-conjugated fraction of CJC-1295 because the DAC-bound form is too large for conventional workflows ^[10][11]. Purity testing that relies only on HPLC without immunoassay or immunoaffinity capture may therefore not capture the full picture of what is in a given preparation.

Anti-doping researchers have developed validated detection methods using immuno-PCR (0.8 pg/mL sensitivity ^[10]) and LC-MS/MS with immunoaffinity capture (180 pg/mL ^[11]) — methods designed for plasma samples, but illustrative of the analytical complexity. A 2010 forensic study confirmed CJC-1295 identity in an illicit preparation using LC-HRMS/MS ^[9].

This site does not have visibility into any supplier's manufacturing or analytical processes and does not endorse or evaluate any source.

What is the half-life of CJC-1295 and how does that affect dosing intervals in research?

CJC-1295's plasma half-life in humans is 5.8–8.1 days, measured in the Teichman 2006 Phase 1/2 trial ^[3]. This is approximately 1,200 times longer than native GHRH (7–10 minutes) and roughly 300 times longer than Modified GRF 1-29 without DAC (~30 minutes) ^[13].

The albumin-binding DAC mechanism explains this: once the covalent thioether bond forms with serum albumin's Cys34, the conjugate circulates as a slow-release depot protected from renal filtration and proteolysis ^[12].

In the Teichman trial, this half-life enabled once-weekly and twice-weekly subcutaneous dosing intervals that maintained IGF-1 above baseline for up to 28 days after the final dose ^[2]. Single-dose GH elevation lasted six days or more, and IGF-1 remained elevated for 9–11 days ^[1].

The practical research implication is that CJC-1295 accumulates with repeated dosing in a way that short-acting peptides do not. Weekly or twice-weekly research protocols in the Teichman trial produced cumulative IGF-1 elevation — a factor relevant to any research design examining downstream effects of sustained GH/IGF-1 axis stimulation.

What happened to CJC-1295 clinical development — why did ConjuChem stop?

ConjuChem Biotechnologies discontinued commercial development of CJC-1295 in 2006 following a participant death in the Phase 2 HIV lipodystrophy trial (NCT00267527). The study investigator attributed the myocardial infarction to pre-existing coronary artery disease rather than the study drug, and no causal relationship to CJC-1295 was established.

Nonetheless, ConjuChem chose not to continue development, and no other sponsor has advanced CJC-1295 to Phase 3 trials. No FDA-approved New Drug Application was ever filed. The December 2024 PCAC meeting reviewed this history and flagged the cardiovascular adverse event — even though attributed to pre-existing disease — as a factor in their negative vote on 503A compounding inclusion ^[14].

The broader context is that ConjuChem's business was built around the DAC platform technology across multiple compounds, not CJC-1295 alone. The company appears to have wound down operations; the trial discontinuation was not accompanied by a published Phase 2 results paper, which means the Phase 2 safety and tolerability data from the HIV lipodystrophy population are not available in the peer-reviewed literature.

What is the difference between CJC-1295 and tesamorelin (the FDA-approved GHRH analog)?

Tesamorelin is an FDA-approved synthetic analog of GHRH (specifically the full 44-amino acid GHRH modified at the N-terminus) indicated for treatment of HIV-associated lipodystrophy — the same indication CJC-1295's discontinued Phase 2 trial targeted. Tesamorelin received FDA approval in 2010 and holds an active NDA.

CJC-1295 is 30 amino acids (based on GRF(1-29)) with the DAC albumin-binding moiety; tesamorelin is based on the full 44-amino acid GHRH sequence with a trans-3-hexenoic acid modification at its N-terminus. They are related pharmacologically — both are GHRHR agonists — but are structurally distinct compounds with different molecular weights, half-lives, and regulatory histories.

CJC-1295 is not approved, has no active NDA, and is not authorized for compounding under current FDA guidance. Tesamorelin is an FDA-approved prescription drug. These are different regulatory categories and should not be conflated.

Why do some sources say CJC-1295 is a GHRP and others say it is a GHRH analog?

This is a nomenclature confusion that appears in non-scientific sources. CJC-1295 is a GHRH analog — it acts on the GHRH receptor (GHRHR) on anterior pituitary somatotrophs, the same receptor that endogenous GHRH uses ^[6].

GHRPs (Growth Hormone Releasing Peptides), such as ipamorelin and GHRP-2, are a distinct class. They act on the ghrelin receptor (GHSR-1a) — a different receptor with a different mechanism. GHRPs and GHRH analogs are complementary, not synonymous.

When CJC-1295 and ipamorelin are studied together, the combination activates two separate GH-stimulating receptors simultaneously. Research in murine models found that GH release from dual GHRH+GHRP receptor activation is synergistic, producing greater GH release amplitude than either compound alone ^[18]. This is why the combination appears in research literature alongside CJC-1295 — they occupy different pharmacological niches rather than duplicate the same mechanism.

Does the 'Legit' in the site name mean you verify CJC-1295 products or suppliers?

No. CJC-1295 Legit is an independent editorial project that summarizes the published research and regulatory record on CJC-1295. The name reflects the editorial frame: a calm, plain-language reading of what the record actually says.

This site does not evaluate suppliers, test products, verify purity claims, or endorse any source of CJC-1295. It does not provide medical advice or research guidance. The 'legit' modifier is about the approach to the literature — honest, unhurried, source-anchored — not about verifying any commercial offering.